Definition
Heinz Feldmann is a German-American virologist and microbiologist renowned for his contributions to the study of high‑containment pathogens, particularly filoviruses such as Ebola and Marburg viruses, as well as for his work in vaccine development and infectious disease research.
Overview
Born on September 29, 1955, in Gummersbach, West Germany, Feldmann earned his medical degree (MD) from the University of Cologne. He later obtained a Ph.D. in virology from the same institution. Feldmann began his research career at the University of Cologne before moving to the United States, where he held positions at the National Institute of Allergy and Infectious Diseases (NIAID) and later at the National Institute of Allergy and Infectious Diseases’ Laboratory of Virology. He has served as the Director of the Laboratory of Virology at NIAID’s Rocky Mountain Laboratories (RML) in Hamilton, Montana.
Feldmann’s research focuses on the molecular biology, pathogenesis, and immunology of emerging viral diseases. He played a pivotal role in the development of experimental vaccines and therapeutic antibodies against Ebola virus, contributing to the pre‑clinical and clinical evaluation of several vaccine platforms, including recombinant vesicular stomatitis virus (rVSV) and adenovirus‑based vectors. His work has been instrumental in advancing the scientific understanding of viral hemorrhagic fevers and informing public‑health responses to outbreaks.
Feldmann is a prolific author, with hundreds of peer‑reviewed articles, book chapters, and conference presentations. He has received numerous awards, including the Gairdner Foundation International Award (2020) for his contributions to vaccine development, and he is a member of several professional societies such as the American Society for Virology and the International Society for Infectious Diseases.
Etymology/Origin
The name “Heinz” is a German diminutive of “Heinrich,” meaning “home ruler.” “Feldmann” is a German surname derived from “Feld,” meaning “field,” and the suffix “‑mann,” meaning “man,” historically indicating a person who worked or lived in the fields.
Characteristics
- Academic Background: MD (University of Cologne), Ph.D. in Virology (University of Cologne).
- Research Areas: Filoviruses (Ebola, Marburg), vaccine development, antiviral therapeutics, viral immunology, high‑containment (BSL‑4) laboratory techniques.
- Key Positions: Director, Laboratory of Virology, Rocky Mountain Laboratories, NIAID; Senior Investigator, Laboratory of Virology, NIAID.
- Major Contributions: Development of rVSV‑based Ebola vaccine (Ervebo™); discovery of protective monoclonal antibodies against filoviruses; elucidation of viral entry mechanisms and host immune responses.
- Publications & Impact: Over 500 scientific papers; h‑index exceeding 120; citation count in the tens of thousands, reflecting high influence in virology and infectious disease fields.
- Professional Service: Editorial board member for journals such as Journal of Virology and PLoS Pathogens; advisor to WHO and CDC on emerging viral threats.
Related Topics
- Ebola virus disease
- Marburg virus disease
- Vaccine platforms (recombinant vesicular stomatitis virus, adenovirus vectors)
- Biosafety level 4 (BSL‑4) laboratories
- National Institute of Allergy and Infectious Diseases (NIAID)
- Emerging infectious diseases
- Immunotherapy for viral infections
All information presented is derived from publicly available, verifiable sources.